North America maintained its dominance in the global plasma fractionation market in 2023, with the United States standing as the largest supplier of plasma fractionation worldwide. A key factor contributing to this leadership is the United States’ policy of paid plasma donations, in contrast to many other countries that rely on volunteer or unpaid donors. This difference significantly impacts the plasma collection rate, with the U.S. enjoying a higher rate of plasma donations. In fact, U.S.-based plasma product companies, including CSL Plasma, Grifols, and BioLife, collect over 75% of the total plasma used for fractionation within the country. There has been a notable increase in the number of plasma donation centers in the U.S., with a 54% rise in the past four years alone. As the demand for plasma continues to grow, the country faces an ongoing need for consistent donation rates, estimated at 6,500 units of plasma per basis.
Canada also plays a crucial role in the global plasma market. The Canadian Blood Service utilizes raw plasma to produce vital plasma-derived products, including plasma proteins, which are essential in treating a range of conditions. As the demand for plasma continues to rise, North America is expected to maintain its leadership in the market for years to come.
Global Plasma Fractionation Market Size and Growth Outlook
The global plasma fractionation market was valued at approximately US$ 32.75 billion in 2023 and is projected to experience substantial growth over the next decade. With a compound annual growth rate (CAGR) of 7.54%, the market is expected to reach US$ 72.86 billion by 2034. This growth is being driven by the increasing therapeutic demand for plasma-derived products, which are essential in treating various medical conditions, from autoimmune diseases to bleeding disorders. As healthcare providers look to meet the growing need for plasma and its derivatives, the market continues to expand, particularly in regions like North America and Europe, where demand for these life-saving products is rising steadily.
Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5320
Europe: Anticipated Growth in Plasma Fractionation Market
In contrast, Europe is projected to experience the fastest growth in the plasma fractionation market over the next decade. This growth is largely influenced by the European Union’s focus on achieving open strategic autonomy and improving competitiveness in the healthcare sector. The European Union, alongside member states and private businesses, is taking action to enhance the resilience of the plasma supply chain. By addressing vulnerabilities and seizing opportunities, Europe aims to establish stronger policies for the supply of plasma and plasma-derived medicinal products. These efforts will support the EU in securing greater recognition in the global plasma fractionation market, creating a solid foundation for future growth.
Market Segment Insights: Dominance and Expansion
In terms of market segments, immune globulin products dominated the plasma fractionation market in 2023. Plasma-derived immunoglobulins have emerged as a crucial component in the healthcare industry, particularly in treating autoimmune inflammatory diseases. These immunoglobulins are vital for patients who are unable to produce sufficient antibodies, offering an externally sourced solution to support recovery.
The coagulation factor segment is expected to see significant growth during the forecast period from 2024 to 2034. Coagulation factors are essential in stopping bleeding after an injury, and their ability to control the conversion of plasma fibrinogen to fibrin, which forms a gel network to stop bleeding, makes them an indispensable part of plasma-derived medicines.
Hospital Segment: Plasma in Emergency Care
The hospital sector accounted for the largest share of the plasma fractionation market in 2023. Plasma is widely utilized in emergency settings to boost blood volume in trauma patients, prevent shock, and aid in blood clotting. Hospitals and other healthcare facilities depend on plasma-derived medicinal products to treat patients with immune deficiency disorders, including HIV, hepatitis, and other serious conditions.
Retail Pharmacy Segment: Fastest Growing Application
Looking ahead, the retail pharmacy sector is expected to grow at the highest compound annual growth rate (CAGR) in the plasma fractionation market. Pharmaceutical companies play a key role in extracting components from raw human plasma, using techniques like centrifugation, depth filtration, and chromatography. This advanced manufacturing process is designed to produce effective and safe medications for patients.
Recent Developments in Plasma Fractionation
Several noteworthy developments are shaping the future of plasma fractionation. In July 2024, Grifols, a leading Spanish pharmaceutical company known for its plasma-derived medicines, appointed Rahul Srinivasan as its new Chief Financial Officer. Srinivasan expressed gratitude for the opportunity to serve in this role, emphasizing Grifols’ impact on patients’ lives through its life-changing portfolio of medicines across various therapeutic areas.
In June 2024, Roland Wandeler, President of Grifols’ Biopharma Business Unit, praised Biotest’s Yimmungo for its potential to expand the availability of intravenous and subcutaneous immunoglobulins. These treatments are essential for patients with primary immunodeficiencies, who rely on immunoglobulin therapies for daily management.
Additionally, innovative collaborations are taking place in the field of plasma-derived therapies. In August 2024, Nanoform Finland partnered with Takeda Pharmaceutical Company to develop pre-clinical plasma-derived therapy formulations. Their collaboration aims to address rare medical conditions by enhancing the effectiveness of plasma-derived treatments.
A groundbreaking initiative was launched in September 2024 with the creation of a joint venture between Grifols and Egypt’s National Service Project Organisation (NSPO). The project aims to achieve self-sufficiency in plasma-derived medicine for Egypt, including the establishment of a plasma laboratory, warehouse, 20 donation centers, and a cutting-edge manufacturing facility. This ambitious national initiative is set to enhance the country’s ability to produce and supply plasma-derived medicines for the treatment of various medical conditions.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fractionation-market-sizing
Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5320
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
